Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 21 of 21 entries
View as:

First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Phase: N/A Priority: Normal
NCT ID: NCT01590407 Org: User:
Start: 12/31/11 End: 02/28/13 Due: 02/28/14

A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study

Phase: N/A Priority: Normal
NCT ID: NCT02588521 Org: User:
Start: 08/31/15 End: 08/14/17 Due: 08/14/18

A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT01790100 Org: User:
Start: 02/28/13 End: 06/30/14 Due: 06/30/15

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir

Phase: N/A Priority: Normal
NCT ID: NCT02569710 Org: User:
Start: 10/31/15 End: 05/11/18 Due: 05/11/19

A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model

Phase: N/A Priority: Normal
NCT ID: NCT02094365 Org: User:
Start: 03/31/14 End: 07/31/14 Due: 07/31/15

A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection

Phase: N/A Priority: Normal
NCT ID: NCT03253471 Org: User:
Start: 07/07/17 End: 09/18/17 Due: 09/18/18

A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT03439488 Org: User:
Start: 03/26/18 End: 10/10/19 Due: 10/10/20

A Study to Assess the PK of AL-794 Formulations in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02877160 Org: User:
Start: 06/30/16 End: 05/31/17 Due: 05/31/18

A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03125213 Org: User:
Start: 09/12/17 End: 02/15/19 Due: 02/15/20

First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Phase: N/A Priority: Normal
NCT ID: NCT02339207 Org: User:
Start: 12/31/14 End: 05/31/16 Due: 05/31/17

A Study of ALS-008176 in Infants Hospitalized With RSV

Phase: N/A Priority: Normal
NCT ID: NCT02202356 Org: User:
Start: 07/23/14 End: 02/15/18 Due: 02/15/19

A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus

Phase: N/A Priority: Normal
NCT ID: NCT02673476 Org: User:
Start: 02/29/16 End: 10/31/16 Due: 10/31/17

A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02512562 Org: User:
Start: 07/31/15 End: 08/31/15 Due: 08/31/16

A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176

Phase: N/A Priority: Normal
NCT ID: NCT02231671 Org: User:
Start: 08/31/14 End: 11/30/14 Due: 11/30/15

A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

Phase: N/A Priority: Normal
NCT ID: NCT02888327 Org: User:
Start: 07/31/16 End: 05/30/17 Due: 05/30/18

Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03032536 Org: User:
Start: 01/31/17 End: 06/28/17 Due: 06/28/18

Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01906164 Org: User:
Start: 05/31/13 End: 11/30/13 Due: 11/30/14

First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT02510248 Org: User:
Start: 07/31/15 End: 11/24/15 Due: 11/24/16

A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03285620 Org: User:
Start: 09/07/17 End: 11/14/18 Due: 11/14/19

First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Phase: N/A Priority: Normal
NCT ID: NCT01554085 Org: User:
Start: 12/31/11 End: 09/30/12 Due: 09/30/13

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03411421 Org: User:
Start: 03/03/18 End: 04/27/18 Due: 04/27/19